References
1. Peter JG, Lehloenya R, Dlamini S,
et al. Severe Delayed Cutaneous and Systemic Reactions to Drugs: A
Global Perspective on the Science and Art of Current Practice. J
Allergy Clin Immunol Pract. 2017;5(3):547-563.
2. Demoly P, Adkinson NF, Brockow K,
et al. International Consensus on drug allergy. Allergy.2014;69(4):420-437.
3. Gomes E, Cardoso MF, Praça F, Gomes
L, Mariño E, Demoly P. Self-reported drug allergy in a general adult
Portuguese population. Clin Exp Allergy. 2004;34(10):1597-1601.
4. Wong SX, Tham MY, Goh CL, Cheong
HH, Chan SY. Spontaneous cutaneous adverse drug reaction reports-An
analysis of a 10-year dataset in Singapore. Pharmacol Res
Perspect. 2019;7(2):e00469.
5. Martínez-Cabriales SA,
Rodríguez-Bolaños F, Shear NH. Drug Reaction with Eosinophilia and
Systemic Symptoms (DReSS): How Far Have We Come? Am J Clin
Dermatol. 2019;20(2):217-236.
6. Zhu N, Zhang D, Wang W, et al. A
Novel Coronavirus from Patients with Pneumonia in China, 2019. N
Engl J Med. 2020;382(8):727-733.
7. Rossi CM, Beretta FN, Traverso G,
Mancarella S, Zenoni D. A case report of toxic epidermal necrolysis
(TEN) in a patient with COVID-19 treated with hydroxychloroquine: are
these two partners in crime? Clin Mol Allergy. 2020;18:19.
8. Schmid-Grendelmeier P, Steiger P,
Naegeli MC, et al. Benralizumab for severe DRESS in two COVID-19
patients. J Allergy Clin Immunol Pract. 2021;9(1):481-483.e482.
9. Balconi SN, Lopes NT, Luzzatto L,
Bonamigo RR. Detection of SARS-CoV-2 in a case of DRESS by
sulfasalazine: could there be a relationship with clinical importance?Int J Dermatol. 2021;60(1):125-126.
10. Manjaly Thomas ZR,
Leuppi-Taegtmeyer A, Jamiolkowski D, et al. Emerging treatments in
COVID-19: Adverse drug reactions including drug hypersensitivities.J Allergy Clin Immunol. 2020;146(4):786-789.
11. Novak N, Peng W, Naegeli MC, et
al. SARS-CoV-2, COVID-19, skin and immunology - What do we know so far?Allergy. 2020;Online ahead of print.
12. Hedou M, Carsuzaa F, Chary E,
Hainaut E, Cazenave-Roblot F, Masson Regnault M. Comment on ’Cutaneous
manifestations in COVID-19: a first perspective’ by Recalcati S. J
Eur Acad Dermatol Venereol. 2020;34(7):e299-e300.
13. Galván Casas C, Català A,
Carretero Hernández G, et al. Classification of the cutaneous
manifestations of COVID-19: a rapid prospective nationwide consensus
study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71-77.
14. Riggioni C, Comberiati P,
Giovannini M, et al. A compendium answering 150 questions on COVID-19
and SARS-CoV-2. Allergy. 2020;75(10):2503-2541.
15. Marzano AV, Genovese G,
Fabbrocini G, et al. Varicella-like exanthem as a specific
COVID-19-associated skin manifestation: Multicenter case series of 22
patients. J Am Acad Dermatol. 2020;83(1):280-285.
16. Azkur AK, Akdis M, Azkur D, et
al. Immune response to SARS-CoV-2 and mechanisms of immunopathological
changes in COVID-19. Allergy. 2020;75(7):1564-1581.
17. Xue X, Mi Z, Wang Z, Pang Z, Liu
H, Zhang F. High Expression of ACE2 on Keratinocytes Reveals Skin as a
Potential Target for SARS-CoV-2. J Invest Dermatol.2020;S0022-202X(20):31602-X.
18. Jamiolkowski D, Mühleisen B,
Müller S, Navarini AA, Tzankov A, Roider E. SARS-CoV-2 PCR testing of
skin for COVID-19 diagnostics: a case report. Lancet.2020;396(10251):598-599.
19. Brüggen MC, Strobl J, Koszik F,
et al. Subcutaneous White Adipose Tissue of Healthy Young Individuals
Harbors a Leukocyte Compartment Distinct from Skin and Blood. J
Invest Dermatol. 2019;139(9):2052-2055.e2057.
20. Eling N, Damond N, Hoch T,
Bodenmiller B.
<em>cytomapper</em>: an
R/Bioconductor package for visualisation of highly multiplexed imaging
data. bioRxiv. 2020:2020.2009.2008.287516.
21. M. K. Building Predictive Models
in R Using the caret Package. Journal of Statistical Software.2008;28(5).
22. Schapiro D, Jackson HW,
Raghuraman S, et al. histoCAT: analysis of cell phenotypes and
interactions in multiplex image cytometry data. Nat Methods.2017;14(9):873-876.
23. Assarsson E, Lundberg M,
Holmquist G, et al. Homogenous 96-plex PEA immunoassay exhibiting high
sensitivity, specificity, and excellent scalability. PLoS One.2014;9(4):e95192.
24. Lind L, Ärnlöv J, Lindahl B,
Siegbahn A, Sundström J, Ingelsson E. Use of a proximity extension assay
proteomics chip to discover new biomarkers for human atherosclerosis.Atherosclerosis. 2015;242(1):205-210.
25. Söderlund S, Christiansson L,
Persson I, et al. Plasma proteomics in CML patients before and after
initiation of tyrosine kinase inhibitor therapy reveals induced Th1
immunity and loss of angiogenic stimuli. Leuk Res.2016;50:95-103.
26. Lang C, Masenga J, Semango G, et
al. Evidence for different immune signatures and sensitization patterns
in sub-Saharan versus central European Atopic Dermatitis patients.J Eur Acad Dermatol Venereol. 2020.
27. Sungnak W, Huang N, Bécavin C, et
al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial
cells together with innate immune genes. Nat Med.2020;26(5):681-687.
28. Radzikowska U, Ding M, Tan G, et
al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated
molecules in tissues and immune cells in health and in asthma, COPD,
obesity, hypertension, and COVID-19 risk factors. Allergy.2020;75(11):2829-2845.
29. Sokolowska M, Lukasik ZM, Agache
I, et al. Immunology of COVID-19: Mechanisms, clinical outcome,
diagnostics, and perspectives—A report of the European Academy of
Allergy and Clinical Immunology (EAACI). Allergy.2020;75(10):2445-2476.
30. Leisman DE, Ronner L, Pinotti R,
et al. Cytokine elevation in severe and critical COVID-19: a rapid
systematic review, meta-analysis, and comparison with other inflammatory
syndromes. Lancet Respir Med. 2020;S2213-2600(20):30404-30405.
31. Sinha P, Matthay MA, Calfee CS.
Is a “Cytokine Storm” Relevant to COVID-19? JAMA Internal
Medicine. 2020;180(9):1152-1154.
32. Zhou F, Yu T, Du R, et al.
Clinical course and risk factors for mortality of adult inpatients with
COVID-19 in Wuhan, China: a retrospective cohort study. Lancet.2020;395(10229):1054-1062.
33. Cummings MJ, Baldwin MR, Abrams
D, et al. Epidemiology, clinical course, and outcomes of critically ill
adults with COVID-19 in New York City: a prospective cohort study.Lancet. 2020;395(10239):1763-1770.
34. de la Rica R, Borges M,
Gonzalez-Freire M. COVID-19: In the Eye of the Cytokine Storm.Frontiers in Immunology. 2020;11(2313).
35. Chen G, Wu D, Guo W, et al.
Clinical and immunological features of severe and moderate coronavirus
disease 2019. J Clin Invest. 2020;130(5):2620-2629.
36. Guan W-j, Ni Z-y, Hu Y, et al.
Clinical Characteristics of Coronavirus Disease 2019 in China. New
England Journal of Medicine. 2020;382(18):1708-1720.
37. Zhang JJ, Dong X, Cao YY, et al.
Clinical characteristics of 140 patients infected with SARS-CoV-2 in
Wuhan, China. Allergy. 2020;75(7):1730-1741.
38. Luo M, Liu J, Jiang W, Yue S, Liu
H, Wei S. IL-6 and CD8+ T cell counts combined are an early predictor of
in-hospital mortality of patients with COVID-19. JCI Insight.2020;5(13).
39. Zhang JY, Wang XM, Xing X, et al.
Single-cell landscape of immunological responses in patients with
COVID-19. Nat Immunol. 2020;21(9):1107-1118.
40. Schulte-Schrepping J, Reusch N,
Paclik D, et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid
Cell Compartment. Cell. 2020;182(6):1419-1440.e1423.
41. Picard D, Janela B, Descamps V,
et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a
multiorgan antiviral T cell response. Sci Transl Med.2010;2(46):46ra62.
42. Yang F, Chen SA, Wu X, Zhu Q, Luo
X. Overexpression of cytotoxic proteins correlates with liver function
impairment in patients with drug reaction with eosinophilia and systemic
symptoms (DRESS). Eur J Dermatol. 2018;28(1):13-25.
43. Kardaun SH, Sidoroff A,
Valeyrie-Allanore L, et al. Variability in the clinical pattern of
cutaneous side-effects of drugs with systemic symptoms: does a DRESS
syndrome really exist? Br J Dermatol. 2007;156(3):609-611.
44. Ushigome Y, Mizukawa Y, Kimishima
M, et al. Monocytes are involved in the balance between regulatory T
cells and Th17 cells in severe drug eruptions. Clin Exp Allergy.2018;48(11):1453-1463.